Tag Archives: intelligence

#437267 This Week’s Awesome Tech Stories From ...

ARTIFICIAL INTELLIGENCE
OpenAI’s New Language Generator GPT-3 Is Shockingly Good—and Completely Mindless
Will Douglas Heaven | MIT Technology Review
“‘Playing with GPT-3 feels like seeing the future,’ Arram Sabeti, a San Francisco–based developer and artist, tweeted last week. That pretty much sums up the response on social media in the last few days to OpenAI’s latest language-generating AI.”

ROBOTICS
The Star of This $70 Million Sci-Fi Film Is a Robot
Sarah Bahr | The New York Times
“Erica was created by Hiroshi Ishiguro, a roboticist at Osaka University in Japan, to be ‘the most beautiful woman in the world’—he modeled her after images of Miss Universe pageant finalists—and the most humanlike robot in existence. But she’s more than just a pretty face: Though ‘b’ is still in preproduction, when she makes her debut, producers believe it will be the first time a film has relied on a fully autonomous artificially intelligent actor.”

VIRTUAL REALITY
My Glitchy, Glorious Day at a Conference for Virtual Beings
Emma Grey Ellis | Wired
“Spectators spent much of the time debating who was real and who was fake. …[Lars Buttler’s] eyes seemed awake and alive in a way that the faces of the other participants in the Zoom call—venture capitalist, a tech founder, and an activist, all of them puppeted by artificial intelligence—were not. ‘Pretty sure Lars is human,’ a (real-person) spectator typed in the in-meeting chat room. ‘I’m starting to think Lars is AI,’ wrote another.”

FUTURE OF FOOD
KFC Is Working With a Russian 3D Bioprinting Firm to Try to Make Lab-Produced Chicken Nuggets
Kim Lyons | The Verge
“The chicken restaurant chain will work with Russian company 3D Bioprinting Solutions to develop bioprinting technology that will ‘print’ chicken meat, using chicken cells and plant material. KFC plans to provide the bioprinting firm with ingredients like breading and spices ‘to achieve the signature KFC taste’ and will seek to replicate the taste and texture of genuine chicken.”

BIOTECH
A CRISPR Cow Is Born. It’s Definitely a Boy
Megan Molteni | Wired
“After nearly five years of research, at least half a million dollars, dozens of failed pregnancies, and countless scientific setbacks, Van Eenennaam’s pioneering attempt to create a line of Crispr’d cattle tailored to the needs of the beef industry all came down to this one calf. Who, as luck seemed sure to have it, was about to enter the world in the middle of a global pandemic.”

GOVERNANCE
Is the Pandemic Finally the Moment for a Universal Basic Income?
Brooks Rainwater and Clay Dillow | Fast Company
“Since February, governments around the globe—including in the US—have intervened in their citizens’ individual financial lives, distributing direct cash payments to backstop workers sidelined by the COVID-19 pandemic. Some are considering keeping such direct assistance in place indefinitely, or at least until the economic shocks subside.”

SCIENCE
How Gödel’s Proof Works
Natalie Wolchover | Wired
“In 1931, the Austrian logician Kurt Gödel pulled off arguably one of the most stunning intellectual achievements in history. Mathematicians of the era sought a solid foundation for mathematics: a set of basic mathematical facts, or axioms, that was both consistent—never leading to contradictions—and complete, serving as the building blocks of all mathematical truths. But Gödel’s shocking incompleteness theorems, published when he was just 25, crushed that dream.”

Image credit: Pierre Châtel-Innocenti / Unsplash Continue reading

Posted in Human Robots

#437265 This Russian Firm’s Star Designer Is ...

Imagine discovering a new artist or designer—whether visual art, fashion, music, or even writing—and becoming a big fan of her work. You follow her on social media, eagerly anticipate new releases, and chat about her talent with your friends. It’s not long before you want to know more about this creative, inspiring person, so you start doing some research. It’s strange, but there doesn’t seem to be any information about the artist’s past online; you can’t find out where she went to school or who her mentors were.

After some more digging, you find out something totally unexpected: your beloved artist is actually not a person at all—she’s an AI.

Would you be amused? Annoyed? Baffled? Impressed? Probably some combination of all these. If you wanted to ask someone who’s had this experience, you could talk to clients of the biggest multidisciplinary design company in Russia, Art.Lebedev Studio (I know, the period confused me at first too). The studio passed off an AI designer as human for more than a year, and no one caught on.

They gave the AI a human-sounding name—Nikolay Ironov—and it participated in more than 20 different projects that included designing brand logos and building brand identities. According to the studio’s website, several of the logos the AI made attracted “considerable public interest, media attention, and discussion in online communities” due to their unique style.

So how did an AI learn to create such buzz-worthy designs? It was trained using hand-drawn vector images each associated with one or more themes. To start a new design, someone enters a few words describing the client, such as what kind of goods or services they offer. The AI uses those words to find associated images and generate various starter designs, which then go through another series of algorithms that “touch them up.” A human designer then selects the best options to present to the client.

“These systems combined together provide users with the experience of instantly converting a client’s text brief into a corporate identity design pack archive. Within seconds,” said Sergey Kulinkovich, the studio’s art director. He added that clients liked Nikolay Ironov’s work before finding out he was an AI (and liked the media attention their brands got after Ironov’s identity was revealed even more).

Ironov joins a growing group of AI “artists” that are starting to raise questions about the nature of art and creativity. Where do creative ideas come from? What makes a work of art truly great? And when more than one person is involved in making art, who should own the copyright?

Art.Lebedev is far from the first design studio to employ artificial intelligence; Mailchimp is using AI to let businesses design multi-channel marketing campaigns without human designers, and Adobe is marketing its new Sensei product as an AI design assistant.

While art made by algorithms can be unique and impressive, though, there’s one caveat that’s important to keep in mind when we worry about human creativity being rendered obsolete. Here’s the thing: AIs still depend on people to not only program them, but feed them a set of training data on which their intelligence and output are based. Depending on the size and nature of an AI’s input data, its output will look pretty different from that of a similar system, and a big part of the difference will be due to the people that created and trained the AIs.

Admittedly, Nikolay Ironov does outshine his human counterparts in a handful of ways; as the studio’s website points out, he can handle real commercial tasks effectively, he doesn’t sleep, get sick, or have “crippling creative blocks,” and he can complete tasks in a matter of seconds.

Given these superhuman capabilities, then, why even keep human designers on staff? As detailed above, it will be a while before creative firms really need to consider this question on a large scale; for now, it still takes a hard-working creative human to make a fast-producing creative AI.

Image Credit: Art.Lebedev Continue reading

Posted in Human Robots

#437261 How AI Will Make Drug Discovery ...

If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?

Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.

But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.

Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.

GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.

But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.

He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.

Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”

The results have turned what was once a decade-long war into a month-long skirmish.

In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.

Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.

They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.

Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.

Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.

But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.

Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.

On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.

Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.

One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.

Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.

Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.

Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.

Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”

How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: andreas160578 from Pixabay Continue reading

Posted in Human Robots

#437224 This Week’s Awesome Tech Stories From ...

VIRTUAL REALITY
How Holographic Tech Is Shrinking VR Displays to the Size of Sunglasses
Kyle Orland | Ars Technica
“…researchers at Facebook Reality Labs are using holographic film to create a prototype VR display that looks less like ski goggles and more like lightweight sunglasses. With a total thickness less than 9mm—and without significant compromises on field of view or resolution—these displays could one day make today’s bulky VR headset designs completely obsolete.”

TRANSPORTATION
Stock Surge Makes Tesla the World’s Most Valuable Automaker
Timothy B. Lee | Ars Technica
“It’s a remarkable milestone for a company that sells far fewer cars than its leading rivals. …But Wall Street is apparently very optimistic about Tesla’s prospects for future growth and profits. Many experts expect a global shift to battery electric vehicles over the next decade or two, and Tesla is leading that revolution.”

FUTURE OF FOOD
These Plant-Based Steaks Come Out of a 3D Printer
Adele Peters | Fast Company
“The startup, launched by cofounders who met while developing digital printers at HP, created custom 3D printers that aim to replicate meat by printing layers of what they call ‘alt-muscle,’ ‘alt-fat,’ and ‘alt-blood,’ forming a complex 3D model.”

AUTOMATION
The US Air Force Is Turning Old F-16s Into AI-Powered Fighters
Amit Katwala | Wired UK
“Maverick’s days are numbered. The long-awaited sequel to Top Gun is due to hit cinemas in December, but the virtuoso fighter pilots at its heart could soon be a thing of the past. The trustworthy wingman will soon be replaced by artificial intelligence, built into a drone, or an existing fighter jet with no one in the cockpit.”

ROBOTICS
NASA Wants to Build a Steam-Powered Hopping Robot to Explore Icy Worlds
Georgina Torbet | Digital Trends
“A bouncing, ball-like robot that’s powered by steam sounds like something out of a steampunk fantasy, but it could be the ideal way to explore some of the distant, icy environments of our solar system. …This round robot would be the size of a soccer ball, with instruments held in the center of a metal cage, and it would use steam-powered thrusters to make jumps from one area of terrain to the next.”

FUTURE
Could Teleporting Ever Work?
Daniel Kolitz | Gizmodo
“Have the major airlines spent decades suppressing teleportation research? Have a number of renowned scientists in the field of teleportation studies disappeared under mysterious circumstances? Is there a cork board at the FBI linking Delta Airlines, shady foreign security firms, and dozens of murdered research professors? …No. None of that is the case. Which begs the question: why doesn’t teleportation exist yet?”

ENERGY
Nuclear ‘Power Balls’ Could Make Meltdowns a Thing of the Past
Daniel Oberhaus | Wired
“Not only will these reactors be smaller and more efficient than current nuclear power plants, but their designers claim they’ll be virtually meltdown-proof. Their secret? Millions of submillimeter-size grains of uranium individually wrapped in protective shells. It’s called triso fuel, and it’s like a radioactive gobstopper.”

TECHNOLOGY
A Plan to Redesign the Internet Could Make Apps That No One Controls
Will Douglas Heaven | MIT Techology Review
“[John Perry] Barlow’s ‘home of Mind’ is ruled today by the likes of Google, Facebook, Amazon, Alibaba, Tencent, and Baidu—a small handful of the biggest companies on earth. Yet listening to the mix of computer scientists and tech investors speak at an online event on June 30 hosted by the Dfinity Foundation…it is clear that a desire for revolution is brewing.”

IMPACT
To Save the World, the UN Is Turning It Into a Computer Simulation
Will Bedingfield | Wired
“The UN has now announced its new secret recipe to achieve [its 17 sustainable development goals or SDGs]: a computer simulation called Policy Priority Inference (PPI). …PPI is a budgeting software—it simulates a government and its bureaucrats as they allocate money on projects that might move a country closer to an SDG.”

Image credit: Benjamin Suter / Unsplash Continue reading

Posted in Human Robots

#437222 China and AI: What the World Can Learn ...

China announced in 2017 its ambition to become the world leader in artificial intelligence (AI) by 2030. While the US still leads in absolute terms, China appears to be making more rapid progress than either the US or the EU, and central and local government spending on AI in China is estimated to be in the tens of billions of dollars.

The move has led—at least in the West—to warnings of a global AI arms race and concerns about the growing reach of China’s authoritarian surveillance state. But treating China as a “villain” in this way is both overly simplistic and potentially costly. While there are undoubtedly aspects of the Chinese government’s approach to AI that are highly concerning and rightly should be condemned, it’s important that this does not cloud all analysis of China’s AI innovation.

The world needs to engage seriously with China’s AI development and take a closer look at what’s really going on. The story is complex and it’s important to highlight where China is making promising advances in useful AI applications and to challenge common misconceptions, as well as to caution against problematic uses.

Nesta has explored the broad spectrum of AI activity in China—the good, the bad, and the unexpected.

The Good
China’s approach to AI development and implementation is fast-paced and pragmatic, oriented towards finding applications which can help solve real-world problems. Rapid progress is being made in the field of healthcare, for example, as China grapples with providing easy access to affordable and high-quality services for its aging population.

Applications include “AI doctor” chatbots, which help to connect communities in remote areas with experienced consultants via telemedicine; machine learning to speed up pharmaceutical research; and the use of deep learning for medical image processing, which can help with the early detection of cancer and other diseases.

Since the outbreak of Covid-19, medical AI applications have surged as Chinese researchers and tech companies have rushed to try and combat the virus by speeding up screening, diagnosis, and new drug development. AI tools used in Wuhan, China, to tackle Covid-19 by helping accelerate CT scan diagnosis are now being used in Italy and have been also offered to the NHS in the UK.

The Bad
But there are also elements of China’s use of AI that are seriously concerning. Positive advances in practical AI applications that are benefiting citizens and society don’t detract from the fact that China’s authoritarian government is also using AI and citizens’ data in ways that violate privacy and civil liberties.

Most disturbingly, reports and leaked documents have revealed the government’s use of facial recognition technologies to enable the surveillance and detention of Muslim ethnic minorities in China’s Xinjiang province.

The emergence of opaque social governance systems that lack accountability mechanisms are also a cause for concern.

In Shanghai’s “smart court” system, for example, AI-generated assessments are used to help with sentencing decisions. But it is difficult for defendants to assess the tool’s potential biases, the quality of the data, and the soundness of the algorithm, making it hard for them to challenge the decisions made.

China’s experience reminds us of the need for transparency and accountability when it comes to AI in public services. Systems must be designed and implemented in ways that are inclusive and protect citizens’ digital rights.

The Unexpected
Commentators have often interpreted the State Council’s 2017 Artificial Intelligence Development Plan as an indication that China’s AI mobilization is a top-down, centrally planned strategy.

But a closer look at the dynamics of China’s AI development reveals the importance of local government in implementing innovation policy. Municipal and provincial governments across China are establishing cross-sector partnerships with research institutions and tech companies to create local AI innovation ecosystems and drive rapid research and development.

Beyond the thriving major cities of Beijing, Shanghai, and Shenzhen, efforts to develop successful innovation hubs are also underway in other regions. A promising example is the city of Hangzhou, in Zhejiang Province, which has established an “AI Town,” clustering together the tech company Alibaba, Zhejiang University, and local businesses to work collaboratively on AI development. China’s local ecosystem approach could offer interesting insights to policymakers in the UK aiming to boost research and innovation outside the capital and tackle longstanding regional economic imbalances.

China’s accelerating AI innovation deserves the world’s full attention, but it is unhelpful to reduce all the many developments into a simplistic narrative about China as a threat or a villain. Observers outside China need to engage seriously with the debate and make more of an effort to understand—and learn from—the nuances of what’s really happening.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image Credit: Dominik Vanyi on Unsplash Continue reading

Posted in Human Robots